Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1093/jpp/rgaf113

http://scihub22266oqcxt.onion/10.1093/jpp/rgaf113
suck pdf from google scholar
41353571!?!41353571

Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=41353571&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215

suck abstract from ncbi

pmid41353571      J+Pharm+Pharmacol 2025 ; ? (?): ?
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Artificial intelligence-enabled nanomedicine: enhancing drug design and predictive modeling in pharmaceutics #MMPMID41353571
  • Sarhan OM; Gebril MI; Elsegaie D
  • J Pharm Pharmacol 2025[Dec]; ? (?): ? PMID41353571show ga
  • The integration of artificial intelligence (AI) and nanomedicine has initiated a revolutionary phase in pharmaceutical research, facilitating progress in targeted drug delivery, controlled release, and personalized therapeutics. This review explores how AI-driven methods are integrated with nanocarrier systems such as liposomes, polymeric nanoparticles, and dendrimers. By harnessing high-dimensional datasets and predictive modeling, advanced techniques like deep learning, reinforcement learning, and graph neural networks have greatly enhanced pharmacokinetic predictions. As a result, dose-response forecasts have become more accurate, development timelines have shortened, and the experimental workload has been reduced. These technologies confront challenges in data standardization, algorithmic transparency, and regulatory adherence. While agencies such as the Food and Drug Administration and European Medicines Agency continue to update their guidelines, there remains an urgent need for a unified, flexible framework that can keep pace with rapid technological progress. This article calls for stronger cross-disciplinary cooperation among computer scientists, pharmaceutical researchers, and regulatory experts to address these challenges and fully harness AI-Enabled Nanomedicine for transforming personalized drug development.
  • ?


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box